New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:02 EDTENDP, BDSIBioDelivery Sciences could be bought by Endo, says Summer Street
Summer Street sees shares of BioDelivery Sciences (BDSI) heading to the $15 level on positive buprenorphine data in July, a drug the company partners with Endo (ENDP). The firm notes Endo could owe up to $70M in milestones to BioDelivery, but it finds it more likely that Endo buys BioDelivery outright. Summer Street keeps a Buy rating on the stock with a $20 price target.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
08:10 EDTENDPEndo appoints Matthew Maletta as Chief Legal Officer
Subscribe for More Information
April 22, 2015
05:53 EDTBDSIBioDelivery Sciences assumed with an Overweight at Piper Jaffray
Subscribe for More Information
April 16, 2015
07:03 EDTENDPEndo price target raised to $110 from $102 at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use